QUESTIONS AND ANSWERS 100

ASPEN Self-Study CNSC EXAM

QUESTIONS AND ANSWERS 100%

SOLVED (Newest 2025) Modular products are used to enhance the nutrient profile of a feeding regimen. Which of the following combinations represents modular products?

• Safflower oil, protaein, glucose and selenium
• Glucose, glutamine, water and MCT oil
• Protein, cholecalciferol, fiber and safflower oil
• MCT oil, glucose, fiber and protein - Correct Answers

✅4. MCT oil, glucose, fiber and protein Protein powders, carbohydrate powders, fat emulsion, MCT oil, fiber and specific amino acids are examples of what? - Correct Answers ✅Modular products Early initiation of enteral feeding has been suggested to benefit ICU patients by reducing infectious complications, length of hospital stay and even possibly reducing mortality.Which group of patients might be at significant risk from early enteral feeding?

• Cancer patients who underwent surgery of the GIT
• Patients with increasing vasopressor support
• TBI patients with intracranial pressure controlled by

hypertonic saline 1 / 4

ASPEN Self-Study CNSC EXAM

QUESTIONS AND ANSWERS 100%

SOLVED (Newest 2025)

• Patients admitted to the hospital with acute on chronic

pancreatitis - Correct Answers ✅2. Patients with increasing vasopressor support What is the risk of feeding a patient before hemodynamic stability has been achieved? - Correct Answers ✅May increase the risk of intestinal ischemia as blood perfusion of the gut may be compromised in a patient who is still requiring high doses of vasopressor drugs to maintain blood pressure When should EN be initiated in the hemodynamically unstable patient? - Correct Answers ✅EN should be delayed until fluid resuscitation is complete A patient with acute respiratory distress syndrome (ARDS) may benefit from a feeding formula containing supplemental

• arginine
• glutamine
• nucleic acids
• omega-3 fatty acids - Correct Answers ✅4. omega-3

fatty acids 2 / 4

ASPEN Self-Study CNSC EXAM

QUESTIONS AND ANSWERS 100%

SOLVED (Newest 2025) Define ARDS. - Correct Answers ✅Acute respiratory distress syndrome - inflammatory response leading to diffuse alveolar damage and lung capillary endothelial injury.Why are formulas containing omega-3 fatty acids recommended in ALI and ARDS? - Correct Answers ✅Inflammatory mediators, including prostaglandins and leukotrienes derived from arachidonic acid metabolism have been implicated in both ALI and ARDS. Formulas containing omega-3 fatty acids may down regulate the inflammatory response through the production of less inflammatory prostaglnadins and leukotrienes What is the evidence for use of omega-3 fatty acids in ARDS and ALI? - Correct Answers ✅Based on 3 level 1 studies the Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient in 2009 recommended patients with ARDS and severe ALI be placed on an enteral formulation characterized by an anti- inflammatory lipid profile. Subsequent to the publication of those guidelines and recommendations have been studies published in 2011 showing that enteral supplementation of omega-3 fatty acids did not result in improved biomarkers of inflammation or clinical outcomes The use of enteral nutrition formulas enriched with BCAAs is

best used for patients with: 3 / 4

ASPEN Self-Study CNSC EXAM

QUESTIONS AND ANSWERS 100%

SOLVED (Newest 2025)

• cirrhosis
• hepatic failure
• liver transplantation
• refractory encephalopathy - Correct Answers ✅4.

refractory encephalopathy What is the theory behind use of BCAAs in hepatic encephalopathy? - Correct Answers ✅There is believed to be an increased ratio of aromatic amino acids to BCAAs in patients experiencing hepatic encephalopathy. The decrease in BCAA is suspected to be due to an increased breakdown in BCAA from skeletal muscles and utilization. The increased levels of AAA generate false neurotransmitters, resulting in hepatic encephalopathy symptoms.What is the evidence for BCAA enriched amino acid enteral formulas? - Correct Answers ✅Published randomized trials have shown mixed results in patients with hepatic failure receiving these specialized formulas. Due to the lack of evidence supporting their use and the increased cost of such products it has been suggested that the use of these hepatic fomulas be limited to patients with encephalopathy refractory to standard medical therapy (lactulose, non-absorbed antibiotics)

• / 4